NCT06235918 is a Phase 2 clinical trial of Tislelizumab in Head and Neck Squamous Cell Carcinomas, sponsored by Xiang Lu.

Who is sponsoring NCT06235918?

NCT06235918 is sponsored by Xiang Lu.

What drugs are being tested in NCT06235918?

Interventions in NCT06235918: Tislelizumab, Nab-paclitaxel, Carboplatin.

What condition does NCT06235918 study?

NCT06235918 studies Head and Neck Squamous Cell Carcinomas, Resectable Head and Neck Squamous-cell Carcinoma.

Is NCT06235918 still recruiting?

NCT06235918 is currently status unknown. Last updated 1 February 2024.

Last reviewed 2024-02-01 · How we verify

NCT06235918

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Status unknown Phase 2 Last updated 1 February 2024

What this trial tests

Phase 2 trial testing Tislelizumab in Head and Neck Squamous Cell Carcinomas in 30 participants. Status unknown.

Timeline

1 January 2023

Primary endpoint
1 January 2025

1 January 2026

Quick facts

Lead sponsor	Xiang Lu
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 January 2023
Primary completion	1 January 2025
Estimated completion	1 January 2026
Sites	1 location across China

Drugs / interventions tested

Tislelizumab (TISLELIZUMAB) — full drug profile →
Nab-paclitaxel (nab-paclitaxel) — full drug profile →
Carboplatin (Carboplatin) — full drug profile →

Conditions studied

Head and Neck Squamous Cell Carcinomas — all drugs for Head and Neck Squamous Cell Carcinomas →
Resectable Head and Neck Squamous-cell Carcinoma — all drugs for Resectable Head and Neck Squamous-cell Carcinoma →

Sponsor

Xiang Lu — full company profile →

Who can join

18 and older, any sex, with Head and Neck Squamous Cell Carcinomas or Resectable Head and Neck Squamous-cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

For resectable squamous cell carcinoma of the head and neck , novel therapeutic approaches are still needed to improve outcomes. Neoadjuvant immunochemotherapy is considered as a potentially effective strategy. The purpose of this study is to evaluate the safety and efficacy of neoadjuvant of tislelizumab combined with platinum doublet for resectable locally-advanced head and neck squamous-cell carcinoma .

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches.
Tufail M, Jiang CH, Li N. · · 2025 · cited 82× · PMID 40739089 · DOI 10.1038/s41392-025-02280-1
Evaluation of neoadjuvant immunotherapy regimens for head and neck squamous cell carcinoma: a systematic review and single-arm and network meta-analysis.
Ye Z, Fan W, Zeng B, Tan R, et al · · 2026 · PMID 41504501 · DOI 10.1097/js9.0000000000004689

Verify or expand the search:

Other trials of Tislelizumab

Trials testing the same drug.

NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting
NCT07290985 — AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas · Phase 2 · not yet recruiting
NCT07518706 — Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · Phase 2 · not yet recruiting

Other recruiting trials for Head and Neck Squamous Cell Carcinomas

Currently open trials in the same condition.

NCT05724329 — Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) · Phase 2 · active not recruiting
NCT04992559 — A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06235918 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiang Lu
Last refreshed: 1 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06235918.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing